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ABSTRACT 
Objective: Thevetia peruviana, an invasive plant with several cardioactive glycosides are grown in different localities of Kerala, India with three 
colour blooms. Present study was carried out to detect various cardiac glycosides in air dried samples; and soxhlet extracts of shade dried, 
powdered leaves of the three morphovariants, using spectrophotometry and chromatography.  
Methods: Determination for total cardiac glycosides in dried samples were carried out at 495 nm, using Baljet’s reagent. After preliminary 
screening on silica coated micro TLC glass plates using chloroform-methanol mobile phase (8:2), separation of various cardiac glycosides and 
quantification of ‘Peruvoside’ (a valuable cardiotonic drug), was achieved using HPTLC, on silica gel 60F254 plates at 220 nm, for CH (chloroform) 
and EA (ethyl acetate) fractions.  
Results: About 2.5-3.37 % of total cardiac glycosides were detected in powdered leaves. Among the successive extracts, both CH (9-11) and EA 
fractions (8-12) occupied different forms of cardiac glycosides, and a good amount of peruvoside was detected either in single or in two isomeric 
forms. The quantity of the drug varied in the order white (8.52 %)>orange (7.16)>yellow (4.97 %) among the three studied plant samples.  
Conclusion: Peruvoside, a notable drug for congestive heart failure has been reported to have anticancerous properties apart from its cardiotonic 
efficacy. Hence, the leaves can be effectively utilized for the successful isolation of this potent drug and other glycosides, without endangering the 
existence of this taxon.  
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INTRODUCTION 
Majority of medicinal plants contain many remarkable compounds 
with exploitable biological properties, sometimes beyond the 
practical reach of synthetic chemicals. Cardiac Glycosides, of course, 
were used as potent heart stimulants from ancient time. Plants with 
these phytochemicals are spread over not less than 34 genera in 
about 11 unrelated families, including Apocynaceae, Asclepiadaceae, 
Liliaceae and Ranunculaceae [1]. They are used to treat severe 
chronic cardiac insufficiency, certain forms of cardiac arrhythmia 
and cardiac shock, and are considered as a single group due to its 
similar pharmacological characteristics [2]. Thevetia peruviana K. 
Schum (= T. neriifolia, Juss) occupied a significant place among the 
many genera of Apocynaceae rich in cardiac glycosides. The genus, 
commonly known as ‘yellow oleander’ belongs to the dogbane family, 
distributed in the tropical and subtropical regions of the world, is now 
naturalized in Indian subcontinent and elsewhere. It grows up to a 
height of 10-15 feet and bears simple, alternate, dark green lanceolate 
foliage, clustered together on slender branchlets. The showy blooms 
usually in yellow, orange or white colours are developed on axillary 
cymes. All plant parts, especially the seeds, were reported to possess a 
huge quantity of therapeutically valuable cardiac principles. 
Chemical examination of Thevetia seed glycosides dates back to 
1863 when DeVry first reported the presence of cardiac glycosides 
and isolated ‘Thevetin’ from its seeds. Since then, there has been 
considerable published literature regarding the therapeutic and 
toxicological aspects of this plant. As many as 15 components were 
isolated from fresh seeds that include Thevetin A, Thevetin B, 
peruvoside, thevebiocide, theveneriin, neriifolin and cerberoside [3]. 
Similarly, about 16-17 compounds (neriifoside, peruvoside, 
oleanolic acid, ursolic acid, lupeol acetate, α-amyrin acetate, β-
amyrin acetate, etc.) were recovered from the fresh and frozen 
leaves of this plant [4, 5]. Two new cardenolides identified were 
termed as Thevetin C and acetyl thevetin C, among the six 
compounds isolated from its leaves [6]. All these studies revealed 
that the plant is a natural source of many cardiac glycosides, which 
could find a useful role in congestive heart failure. 
Heart diseases are increasing day by day due to many known and 
unknown reasons. Availability of life saving drugs is beyond the 
reach of common people. In order to compensate the increasing 
demand of cardiotonic drugs, isolation of powerful compounds from 
natural resources through cost-effective method is essential. 
Moreover, plants are the chief source of cardiac glycosides and their 
synthesis is difficult due to their high structural peculiarity. Since 
there are overwhelming reports regarding the existence of a series 
of glycosides in various plant parts, it is relevant to make a 
comparative quantitative study regarding the occurrence of various 
cardiac glycosides, principally ‘Peruvoside’ in the leaves of three 
colour variants grown in Kerala, the Southern State of India.  
MATERIALS AND METHODS  
Plants are commonly cultivated as ornamentals in Trichur Dist, 
Kerala. Fresh twigs were collected from three morphovariant plants; 
and the authenticated herbarium specimens (STHAPC 2458a-c) are 
maintained in the Department of Botany, St. Teresa’s College, 
Ernakulam. Materials were washed thoroughly in running tap water 
to remove adhering dust particles and other contaminants. To avoid 
the loss of phytoconstituents via latex of wounded ends, twigs were 
allowed to dry in shade for 2-3 weeks, at room temperature. 
Withered leaves were collected from dried twigs, finely powdered 
and kept in airtight containers till further assays were done. 
Quantitative estimation of total cardiac glycosides 
One gram each of powdered samples was soaked overnight in 10 ml 
of 70 % alcohol and filtered. Based on lactone ring, total cardiac 
glycosides in the raw samples were estimated using Baljet’s reagent, 
described by El-Olemy et al., [7]. One ml of extract was purified using 
12.5 % lead acetate and 4.77 % Na2HPO4 solution before the 
addition of freshly prepared Baljet’s reagent (95 ml of 1 % aqueous 
picric acid+5 ml 10 % aqueous NaOH). The intensity of the color 
produced is proportional to the concentration of the glycoside. The 
absorbance was measured using spectrophotometer at 495 nm 
against blank (distilled water) and the concentration of the glycoside 
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was calculated. Appearance of deep orange color, a character of 
digitalis cardiac glycosides, indicated the presence of lactone ring in 
the agycone part of cardenolides, after the reaction. 
Soxhlet extraction 
Accurately weighed leaf samples (30 g) were extracted successively 
with 300 ml each of PE (60-80 °C, petroleum ether), CH 
(chloroform), EA (ethyl acetate) and MT (methanol) in a Soxhlet 
extractor for 12-18 h [8]. The extracts were concentrated to dryness, 
weighed and kept in labelled bottles at 4 ◦C for further studies.  
Sample preparation 
Preliminary phytochemical screening and Thin Layer Chromatography 
(TLC) were carried out using appropriate dilutions of samples in 
corresponding solvents. The suitable solvent system was optimized to 
achieve the best resolution for cardiac glycosides (chloroform-
methanol 8:2) in favor of chromatographic analysis. For High 
Performance Thin Layer Chromatographic (HPTLC) studies, 
chlorophyll pigments were precipitated by treating the samples with 
10 % lead acetate and a final concentration of 10 mg/ml was made 
ready for fingerprinting. Detecting reagents sulfuric acid and 
Libermann Burchard were used to perceive various cardiac glycosides, 
especially for ‘Peruvoside’ in TLC and HPTLC plates respectively. 
Reference compound ‘Peruvoside’ (Sigma-Aldrich, CAS Number 1182-
87-2) was diluted to a concentration of 1.0 mg/ml. 
HPTLC instrumentation 
Analysis was performed using commercially available pre-coated 
silica gel 60F254 plates (E. Merck KGaA) on the Camag-HPTLC 
system (Germany). To estimate the quantity of peruvoside and 
other cardiac glycosides, an aliquot of 5 µl sample (three samples, 
each of CH and EA fractions) and standard drug were loaded in a 
plate of 10 x 10 cm size as 9 tracks of 6 mm band width. The plate 
was developed up to a height of 85 mm in a twin trough 
developing chamber saturated with 10 ml of chloroform methanol 
mixture (8:2) mobile phase. After drying, the developed plate was 
visualized under UV light at 254 and 366 nm wavelengths and day 
light. Densitometric scanning was performed in the absorbance 
mode at 220 nm at a scanning speed of 20 mm/s through a 4.00 x 
0.30 mm dimension slit. The plate was derivatised with Libermann 
Burchard reagent and images were captured again at all 
illumination modes. Bands for ‘Peruvoside’ in the samples was 
ascertained by comparing the Rf values and spectra of samples 
with those of the standard compound [9]. 
RESULTS 
Cardiac glycosides usually do not get precipitated with lead acetate. 
Using Baljet reagent, a total of 3.37, 2.52 and 3.2 % glycosides were 
estimated in the dried leaves of yellow, orange and white variants, 
respectively.  
Preliminary screening experiments showed that, of the four 
fractions analyzed, ‘Peruvoside’ was detected in CH and EA fractions, 
whereas it was absent in PE and MT fractions. Nonpolar solvent PE 
usually acts as a defatting agent, and they do not dissolve cardiac 
glycosides. Consequently, these metabolites were quantified in 
positive fractions. Bands for ‘Peruvoside’ in HPTLC plates were 
detected as compact yellow ones under shorter (254 nm) and longer 
(366 nm) wavelengths without derivatization. Before routine 
analyses the method need to be validated in the pharmaceutical 
environment. Initially, the repeatability of ‘Peruvoside’ application 
and measurement of peak area was carried out using three 
replicates on the same plate with 5, 10 and 15 μg/spot, to generate 
calibration curve.  
The linear regression analysis data for the calibration plots 
showed a good linear relationship with r2 = 0.9921 in the 
concentration range 5-15 µl with respect to peak area. HPTLC 
profiling of standard drug and eluted compounds in various leaf 
samples is illustrated in fig.1. 
Total cardiac glycosides eluted during chromatography from CH and 
EA fractions of yellow variant leaves (YLCH & YLEA) were tabulated 
in table 1. Both fractions showed 11 and 8 peaks, and each peak 
represents different forms of cardiac glycosides. Of which, only 6 
compounds were identical with respect to the Rf value. The 
remaining ones were observed in any one of the solvent fractions. 
The elution phase of the biological reference compound was found 
in the range of 0.62 to 0.71 with±0.02 deviation. In the EA fraction, 
similar elution was achieved by a compound (peak no. 9) with a 
moderate area of 14.22 %; but in less polar solvent (CH), the same 
compound splits apart as two analogous or isomeric compounds 
(peaks 9,10), sharing the Rf range of standard compound. Similarly, 
in orange color variant, both fractions occupied 9 cardiac glycosides 
each. Out of this, 7 metabolites have comparable Rf values, including 
the analyte under study, and only two differed each other (table 2). 
Likewise, the occurrence of ‘Peruvoside’ appeared quantitatively more 
in EA fraction (17.25 % area) as a single compound, than CH which 
split into two isomers and appeared as two peaks (12.11 area %).  
As expected, chromatogram of the white variant possessed a series 
of 10-12 cardiac glycosides (table 3). In contrast to the above two 
observations, here, the compound of interest in the CH sample did 
not convert into two isomeric forms and showed a major area of 
13.6 %, but in EA fraction, two identical forms with a minor 
deviation in Rf value was quantified. Quantity of peruvoside was 
calculated taking various parameters like dilution factors, area of 
analytes, etc. 
 
Table 1: Comparative densitogram showing Rf values and area of compounds (in %) in CH and EA fractions of leaf extract of yellow 
variant and standard ‘Peruvoside’(fig. 1: B, G, J) 
Peak  
No. 
YLCH (11) YLEA (8) 
Start Rf Max Rf End Rf Area Area % Start Rf Max Rf End Rf Area Area % 
1 0.02 0.05 0.06 11018.7 30.30 0.00 0.04 0.05 9653.3 20.53 
2 - - - - - 0.08 0.10 0.11 186.5 0.40 
3 0.13 0.15 0.17 231.0 0.64 - - - - - 
4 0.28 0.29 0.32 853.0 2.35 - - - - - 
5 0.33 0.34 0.35 312. 3 0.86 - - - - - 
6 - - - - - 0.38 0.45 0.46 1962.1 4.17 
7 0.45 0.47 0.48 517.1 1.42 - - - - - 
8 0.51 0.55 0.57 2287.9 6.29 0.49 0.57 0.57 3409.2 7.25 
9 0.62 0.64 0.66 2717.3 7.47 0.60 0.64 0.69 6686.9 14.22 
10 0.66 0.68 0.69 1307.1 3.59 - - - - - 
11 0.69 0.70 0.75 2726.0 7.50 0.70 0.74 0.75 3567.8 7.59 
12 0.79 0.85 0.92 7867.9 21.63 0.78 0.84 0.91 12519.8 26.62 
13 0.92 0.98 1.00 6528.3 17.95 0.92 0.98 1.00 9042.9 19.23 
Std 0.63 0.67 0.70 19400.7 48.37 - - - - - 
YLCH, YLEA–chloroform (CH) and ethyl acetate (EA) fractions of leaves (L) of yellow(Y) variant  
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Table 2: Comparative densitogram showing Rf values and area of compounds (in %) in CH and EA fractions of leaf extract of orange 
variant (fig. 1: H. K) 
Peak 
No. 
OLCH (9) OLEA (9) 
Start Rf Max Rf End Rf Area  Area % Start Rf Max Rf End Rf Area Area % 
1 0.01 0.04 0.07 9526.3 23.79 01 0.04 0.06 10174.4 16.55 
2 0.18 0.23 0.25 387.6 0.97 - - - - - 
3 - - - - - 0.35 0.37 0.40 1119.3 1.82 
4 - - - - - 0.40 0.45 0.47 2220.7 3.61 
5 0.47 0.56 0.57 3227.4 8.06 0.47 0.51 0.53 3430.1 5.58 
6 0.57 0.60 0.62 2107.0 5.26 0.54 0.59 0.60 3550.6 5.78 
7 0.62 0.64 0.66 3200.9 7.99 0.60 0.64 0.70 10603.9 17.25 
8 0.66 0.67 0.70 1648.6 4.12 - - - - - 
9 0.70 0.72 0.76 2552.2 6.37 0.70 0.74 0.79 9185.2 14.94 
10 0.78 0.85 0.93 10327.3 25.79 0.79 0.84 0.92 13608.2 22.14 
11 0.93 0.98 1.00 7067.0 17.65 0.93 0.98 1.00 7581.1 12.33 
OLCH, OLEA–chloroform (CH) and ethyl acetate (EA) fractions of leaves (L) of orange (O) variant  
 
Table 3: Comparative densitogram showing Rf values and area of compounds (in %) in CH and EA fractions of leaf extract of white variant 
(fig. 1: I, L) 
Peak  
No. 
WLCH (10) WLEA (12) 
StartRf MaxRf EndRf Area Area % Start Rf Max Rf End Rf Area Area % 
1 0.01 0.04 0.05 7736.0 18.58 0.01 0.05 0.06 12852.6 18.46 
2 0.07 0.09 0.11 244.6 0.59 - - - - - 
3 - - - - - 0.11 0.13 0.14 89.7 0.13 
4 0.17 0.19 0.21 198.4 0.48 - - - - - 
5 - - - - - 0.23 0.28 0.30 1076.9 1.55 
6 - - - - - 0.30 0.33 0.36 1569.3 2.25 
7 0.41 0.44 0.45 679.9 1.63 - - - - - 
8 0.47 0.54 0.56 2824.4 6.78 0.45 0.49 0.50 1901.1 2.73 
9 - - - - - 0.50 0.56 0.57 4604.9 6.61 
10 0.57 0.59 0.61 1860.5 4.47 0.57 0.62 0.65 9167.6 13.16 
11 0.62 0.64 0.71 5660.7 13.60 0.66 0.67 0.69 3525.4 5.06 
12 0.71 0.72 0.75 1744.0 4.19 0.70 0.75 0.76 7116.5 10.22 
13 0.77 0.85 0.92 12150.1 29.19 0.76 0.77 0.79 2644.5  3.80 
14 - - - - - 0.79 0.83 0.92 16134.6 23.17 
15 0.92 0.96 1.00 8529.6 20.49 0.92 0.96 1.00 8953.2 12.86 
WLCH, WLEA–chloroform (CH) and ethyl acetate (EA) fractions of leaves (L) of white (W) variant 
  
 
Fig. 1: HPTLC fingerprint analysis on Cardiac Glycosides of Thevetia peruviana leaf extracts of three morphovariant plants using standard 
drug ‘Peruvoside’ 
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A) 3D display of Chromatogram of leaf fractions (tracks 1-3 standard 
drug peruvoside; 4-6 chloroform fractions; 7-9 ethyl acetate 
fractions) B) Chromatogram of ‘Peruvoside’ at 220 nm at track 1; C-
D) before derivatization at UV 254 nm and 366 nm; E-F) after 
derivatization at daylight and 254 nm; G-I) comparative 
densitogram display of CH fractions at tracks 4-6; and J-L) EA 
fractions at tracks 7-9 in the order yellow, orange and white forms, 
scanned at 220 nm. 
 
Table 4: Quantity of ‘Peruvoside’ distribution in different parts of T. periviana morphovariants (leaves, flowers [10], rind [11] and seeds [12]) 
Sample Quantity/ 
Sample(%) 
Total quantity (%) sample Quantity/ 
Sample(%) 
Total quantity (%) sample Quantity/ 
Sample(%) 
Total quantity (%) 
YLCH 1.87 4.97 OLCH 2.23 7.15 WLCH 2.63 8.52 
YLEA 3.10 OLEA 4.92 WLEA 5.89 
YFCH 12.41 13.69 OFCH 9.26 10.1 WFCH 11.41 11.59 
YFEA 1.28 OFEA 0.84 WFEA 0.18 
YRCH 2.72 3.26 ORCH 2.64 3.24 WRCH 1.87 3.07 
YREA 0.54 OREA 0.60 WREA 1.2 
YSCH 3.24 20.18 OSCH 7.26 19.71 WSCH 6.03 19.47 
YSEA 16.94 OSEA 12.45 WSEA 13.44 




There is no obvious pattern for the occurrence of various 
metabolites in different plants and plant parts. Around 2.5-3.4 % of 
total cardiac glycosides were quantified in air dried, powdered leaf 
samples, using Baljet’s reagent. The varied distribution of cardiac 
glycosides was reported as 4.27 and 4.70 % of the raw seeds of 
Thevetia [13, 14]. Likewise, Sun and Libizor [15] noticed 3.6-4.0 % 
thevetin as the major glycoside in the seeds.  
The results obtained during the ongoing investigations on the 
quantification of ‘Peruvoside’ in diverse plant parts of three 
morphoforms varied considerably, and are summarized in table 4. It 
is noteworthy to point out the efficacy of organic solvents-CH and EA 
in extracting maximum ‘Peruvoside’ without leaving any traces for 
further extraction by MT. An average quantity of extractable 
‘Peruvoside’ was present in CH and EA fractions of leaf extracts 
(4.97-8.52 %), either in intact form or in two isomeric forms. Earlier 
studies revealed that around one fifth portion of CH and EA fractions 
of seeds [12] contained this valuable drug (19.47-20.18 %). Most 
surprisingly, a good amount (10.1-13.69 %) could be tapped even 
from withered flowers [10], and a fair amount (3.07-3.26 %) from 
unused and neglected fruit rind walls [11], clarified that they were 
distributed throughout the plant, and their intensity varied from 
organ to organ. 
Cardiac glycosides are usually soluble in water and alcohol and 
insoluble in fat organic solvents with the exception of CH and EA. 
Compounds with higher number of sugar are soluble in water and 
lower number in CH [16]. Accordingly, many of the compounds 
extracted using CH and EA can be considered as stable compounds 
with lesser number of sugar molecules. Usually, the glycosides are 
susceptible to hydrolysis by enzymes during extraction process. The 
acetyl group and the glucose are split off, but fortunately the partly 
hydrolyzed glycosides such as digoxin and digitoxin are as 
biologically active as the parent compound [16].  
Minute variations were observed regarding the number of cardiac 
glycosides present in the same fraction of morphovariant plants 
(YLCH-11, OLCH-9, WLCH-10). This variation could be more 
correlated with various enzyme actions and other metabolic changes 
that could happen from harvesting time onwards. The difference in 
the constituent profile of the plant material may be affected by 
several environmental factors (temperature, light, rain, soil pH, etc.) 
harvesting time, drying methods, extraction methods and its 
duration, enzymatic reactions during storage, etc. [17]. According to 
natural rules, cardiac glycosides vary in availability both 
qualitatively and quantitatively. Due to the complex chemical nature 
of this group, more cardiac glycosides are continuously added to the 
database, in addition to the existing molecules, and the possibility of 
biological conversion depends on a number of criteria. Among the 
possible views related to the variations observed in the number of 
glycosides, it will be relevant to discuss the nature of cardiac 
glycosides during hydrolysis. 
Natural cardiac glycosides found in plants are the precursor 
molecules, which upon alkaline and enzymatic hydrolysis yield 
various secondary glycosides by giving up one or more sugar 
molecules, which on further hydrolysis produces stable tertiary 
compounds. Because of greater stability of secondary glycosides, and 
lesser absorption of primary glycosides, a higher content of the 
latter is not ideal for direct therapeutic usage [18]. Upon acid 
hydrolysis, the sugars are cleaved leaving the aglycone or genin, that 
makes it inactive [6]. In plants, the hydrolyzing enzymes usually co-
exist with cardiac glycosides, but in different cells or compartments. 
Glycosides are stored in vacuoles, protected from hydrolytic 
enzymes of cytoplasm and usually specific enzymes hydrolyzes 
specific cardiac glycosides. Primary glycosides from its storage 
region pass across the tonoplast, with the aid of a specific carrier 
protein [19], and might be reached all over the plant body. In a 
number of species, the site of biosynthesis is restricted to one organ, 
whereas the products are accumulated all over the plant or in 
different organs and cells [20]. In Thevetia peruviana, the site of 
biosynthesis of cardiac glycosides could be considered as the 
photosynthetic vegetative part and might be transported to various 
reproductive parts where they accumulate, that accounts for the 
irregular distribution of ‘Peruvoside’ and other cardiac glycosides in 
various plant parts.  
‘Thevetin’, the primary glycoside of T. peruviana, gives off two 
trioses: Thevetin A and B (secondary glycosides). Further hydrolysis 
leads to the production of tertiary glycosides: cerberin, neriifolin, 
peruvoside, ruvoside and peruvosidic acid [3]. Most of the extracted 
glycosides are the partial enzyme hydrolytic products of natural 
ones [2]. A wide range of semi synthetic and synthetic analogues 
have been prepared by introducing suitable modifications on 
isolated natural compounds, to determine the essential structural 
requirements for displaying cardiotonic activity, and to obtain 
derivatives with less toxicity [21]. To improve the pharmacological 
properties of natural cardiac glycosides, chemical and biochemical 
transformations are necessary. Furthermore, enzymatic 
biotransformation of peruvoside and neriifolin from yellow oleander 
gives digoxin [22]. The therapeutic potential of cardiac glycosides, 
including anticancer and antitumor effects was widely discussed by 
many investigators [23, 24].  
CONCLUSION 
Thevetia peruviana, ‘the yellow oleander’, one among the Indian 
indigenous plants, contain a mixture of several cardiac glycosides. 
Since different plant parts find use in various folk medicines and 
other clinical applications, and the plant material is the only 
industrial source for cardiac glycoside availability, it is important to 
establish the quality and quantity of various components in 
constituent plant parts.  
About 15-18 types of cardiac glycosides exist in leaves and other 
parts which were distributed unevenly throughout the plant, some 
being common in all plant parts. Cardiac glycosides can undergo 
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hydrolysis at any time, from the time of harvest. If injury occurs to 
plant parts at the time of collection, the enzymes compartmentalized 
in cells mix with glycosides residing in the vacuole, leading to 
unpredictable breakdown of compounds. This results in the collapse 
of parent glycosides at various levels, which ultimately leads to the 
formation of different types of molecules or isomers, and hence, the 
process and method of extraction are very sensitive. Minor 
qualitative and quantitative variations occur in naturally distributed 
flora, unquestionably. 
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